3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Interventions
enzalutamide
8
Abiraterone Acetate
4
rucaparib
2
Prednisone
2
Docetaxel
2
sabizabulin
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration Resistant Prostate Cancer
×
Pluvicto
×
Clear all
NCT03042312
2021-03-24
RESIST-PC
Endocyte
Phase 2
Terminated
71 enrolled
15 charts